Pineal tetrapeptide
Epithalon
Epithalon after one dose: 50% at ~3 h, 25% at 6 h, 12.5% at 9 h.
Drawn from the half-life in the app's model, ~3 h. The model's figures
- Compound
- Epithalon
- Symbol
- EPI
- Family
- Healing peptides
- Parts
- 14
- References
- 15
- Checked
- Last reviewed . Sources are listed below.
Overview
Epithalon, also spelled epitalon and abbreviated AEDG after its amino acids, is the tetrapeptide Ala-Glu-Asp-Gly.2,1 It was developed from the amino-acid composition of epithalamin, a polypeptide extract of the bovine pineal gland, and FDA states that it considers epitalon and epithalamin to be different substances.1,2
FDA's July 2026 briefing document states that no pharmacokinetic data were found for epitalon free base or epitalon acetate, and that there are no clinical data to support the safety of either in humans.2 Jain and colleagues, in a 2026 narrative review in the International Journal of Molecular Sciences, describe the human evidence as limited to small physiological or biomarker studies and an older controlled study in retinitis pigmentosa, with no adequately powered randomized trial establishing therapeutic efficacy.1 A search of PubMed on 16 November 2026 for epithalon or epitalon in the title or summary text returned 116 records, and a search of ClinicalTrials.gov for the same terms returned 1 registered study, which lists epitalon as one of five peptides in a topical serum.3
How it works
Jain and colleagues state that much of the historical epitalon literature originates from a limited number of collaborating investigators, and that epitalon "was developed and extensively investigated by Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology".1
One proposed mechanism is activation of telomerase, the enzyme that adds telomere structures to the ends of chromosomes.2 Khavinson, Bondarev and Butyugov reported in the Bulletin of Experimental Biology and Medicine in 2003 that adding epithalon to a telomerase-negative human fetal fibroblast culture induced expression of the catalytic subunit, telomerase activity and telomere elongation.4 FDA's briefing document describes that work as primary cultures of human fetal lung fibroblasts incubated with epitalon at 50 ng/mL for 4 days.2
Deeper analysis: the 2025 cell study from Brunel University London
Al-Dulaimi, Thomas, Matta and Roberts, of Brunel University London, reported in Biogerontology in 2025 on two breast cancer cell lines (21NT and BT474) and two normal human cell lines (IBR.3 fibroblasts and HMEC epithelial cells).5 Cancer cells were treated daily with 0.1, 0.2, 0.5 or 1.0 µg/mL for 4 days and normal cells with 1.0 µg/mL for 3 weeks.5 In IBR.3 cells, 4 days of treatment gave no increase in telomere length (data not shown in the paper), while 3 weeks gave a significant increase in IBR.3 and HMEC cells and an increase in telomerase activity; the authors state that normal cells need the longer, 3-week incubation.5 In the cancer cells, telomere length also increased, but telomerase activity did not significantly increase; ALT activity (alternative lengthening of telomeres) rose ten-fold in 21NT and three-fold in BT474.5 The authors state that the main limitation is that this was "an in vitro study using human cell lines in 2D cell cultures".5 The authors declare no competing interests, report funding from their department and self-funding PhD students, and state that the epitalon was purchased from UK Peptides.5 Jain and colleagues note that a later correction states that the first three figures of the original publication were incorrect and were replaced, and they write that the reported telomerase-activity findings need cautious interpretation.1
Melatonin and the pineal gland
A second proposed mechanism is an effect on the pineal gland's melatonin output.2 In a perifusion study of pineal glands from male Wistar rats aged 9 weeks and 27 months, Djeridane and colleagues reported in the Journal of Endocrinological Investigation in 2003 that the tetrapeptide at 10(-4) to 10(-6) M had no significant effect upon melatonin secretion at either age.6 FDA's briefing document states that "the mechanisms by which epitalon regulates serum levels of melatonin in vivo remain unknown".2
In female rhesus monkeys given 2 µg/kg intramuscularly for 10 days, Goncharova and colleagues reported in the Bulletin of Experimental Biology and Medicine in 2001 that evening melatonin rose by more than 4-fold and evening cortisol fell by about 30% in the old monkeys, with no statistically significant change in morning values, according to FDA's account of the paper.2 In the young monkeys the same account reports no significant effect on melatonin and lower cortisol in the morning and the evening.2
Deeper analysis: the 2003 mouse lifespan study
Anisimov and colleagues, including Khavinson, reported in Biogerontology in 2003 on female Swiss-derived SHR mice, 54 per group for lifespan and tumor outcomes, injected subcutaneously from 3 months of age until natural death with saline or 1.0 µg per mouse (approximately 30 to 40 µg/kg) of epitalon on 5 consecutive days every month.7 Epitalon did not influence food consumption, body weight, mean life span or total spontaneous tumor incidence.7 It increased the life span of the last 10% of survivors by 13.3% (P<0.01) and maximum life span by 12.3%, decreased chromosome aberrations in bone marrow cells by 17.1% (P<0.05), and, the authors report, inhibited the development of leukemia (6.0-fold).7 The authors conclude that the data suggest geroprotector activity of epitalon and the safety of its long-term administration in mice.7 FDA's briefing document cautions that the lifespan and tumor studies used a fixed dose, assessed only female mice and gave exposures far shorter than 12 months, so they do not adequately inform the genotoxic or carcinogenic potential of epitalon.2 FDA adds that the chromosome-aberration endpoint used n = 4 per treatment group, that the research group appears to have used the frequency measured in four saline-treated SHR mice as historical control data without an analysis to validate it, and that the data from all studies are to be "interpreted with caution".2
Pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~3 h
- Bioavailability
- 95%
- Typical dose
- 5–10 mg/day
- Route
- SubQ
- Time to peak
- ~30 min
Sources in this part
The app lists a half-life of about 3 hours, a bioavailability of 95% by subcutaneous injection and a time to peak of about 30 minutes for epithalon. FDA's briefing document, by contrast, states that "No pharmacokinetic data were found for epitalon (free base) or epitalon acetate".2 FDA identified one preliminary distribution report, a study in pregnant rabbits given a single intravenous dose of fluorescent-labeled epitalon (30 µg/kg), in which fluorescence could be detected one hour after dosing in maternal and fetal organs including the liver and lungs, and no additional pharmacokinetic or toxicokinetic studies.2 FDA states that the study "lacks data to demonstrate that the fluorescence signals detected in tissue were specifically due to labeled epitalon".2
| Figure | The app | Sources |
|---|---|---|
| Half-life | ~3 hours | None reported; FDA identified no pharmacokinetic data and one preliminary rabbit distribution study.2 |
| Time to peak | ~0.5 hours | None reported; FDA identified no pharmacokinetic data.2 |
| Bioavailability | 95% (subcutaneous) | None reported; oral dosing in aged rats altered intestinal glucose transport but did not establish systemic bioavailability of intact epitalon.1 |
| Route | Subcutaneous | Human studies used intramuscular, sublingual and parabulbar routes.1 |
Human studies
Jain and colleagues identified 31 unique primary research publications on epitalon or epithalamin through 22 September 2026, of which 28 evaluated epitalon; 4 of those 28 involved human participants and 24 were preclinical, mechanistic or analytical studies.1 FDA's briefing document identifies three studies in which epitalon was given to humans: two sublingual studies in night-shift workers and one parabulbar injection study in retinitis pigmentosa.2
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Khavinson and colleagues, 20028 | Controlled clinical study; randomization and blinding not clearly described; control group on conventional therapy1 | 162 patients (324 eyes) aged 18–72 years with congenital retinitis pigmentosa; control 46 patients (92 eyes)1 | 5.0 µg per eye once daily for 10 days, parabulbar1 | Positive clinical effect reported in about 90% of treated cases; no treatment-related complications described8,1 |
| Korkushko and colleagues, 20079 | Human interventional study; blinding not clearly described1 | Elderly adults with age-related pineal melatonin dysfunction: 15 epithalamin, 15 epitalon, 10 placebo; 10 young reference subjects1 | 0.01 mg per day intramuscularly for 10 days1 | Night melatonin rose in people with pineal gland functional insufficiency; the English summary states "no side effects"9 |
| Ivko and colleagues, 2020 and 202110 | Randomized biomarker study; blinding not specified1 | 75 women aged 40–50 years, mostly night-shift workers: 35 reference, 40 with reduced melatonin production randomized to 20 placebo and 20 AEDG1 | 0.5 mg per day sublingually for 20 days1 | Baseline urinary 6-sulfatoxymelatonin 1.7 times below the reference group; placebo group unchanged; AEDG group up 1.7-fold, to a normal, age-appropriate value in the authors' words as quoted by FDA2; Clock and Csnk1e expression shifted toward reference values; Cry2 expression increased1 |
A fourth publication, Khavinson, Linkova and Ivko in 2021, examined a highly similar population of 75 women, and Jain and colleagues treat it as a closely related analysis, not independent replication.1
Deeper analysis: the retinitis pigmentosa study
Khavinson, Razumovsky, Trofimova, Grigorian and Razumovskaya reported in Neuroendocrinology Letters in 2002, with affiliation to the St. Petersburg Institute of Bioregulation and Gerontology, the institution where Jain and colleagues state epitalon was developed.8,1 The paper also reports an effect of epitalon in Campbell rats with congenital pigmented degeneration of the retina, and states that the human therapy "results in a positive clinical effect in 90% of the cases".8 Araj and colleagues, in a 2025 review, add that visual acuity in treated patients increased by 0.15 to 0.20 on average and that the total visual field border broadened by 90 to 120 degrees in 64.8% of patients; the review is a secondary account that gives no control-group values and no control-group size.11 Jain and colleagues state that the absence of a clearly described allocation procedure, masking and placebo control "substantially limits causal interpretation," and that the study is a single-center report without independent replication.1 No funding statement appears in the PubMed record for the 2002 paper.8
Deeper analysis: the night-shift melatonin study
Ivko, Linkova, Ilina, Sharova and Ryzhak, whose affiliation in the PubMed record is the Institute of Predictive Medicine in Limassol, Cyprus, reported in Advances in Gerontology in 2020 that AEDG increased urinary 6-sulfatoxymelatonin excretion 1.7 times in middle-aged people with reduced melatonin-producing function, and shifted Clock and Csnk1e expression down by 1.9 to 2.1 times and Cry2 expression up by 2 times.10 FDA's briefing document describes the study it cites as Ivko 2021 as a randomized, placebo-controlled study in healthy women aged 40 to 50 years (n = 75), primarily working night shifts.2 Of these, 40 with low urinary 6-sulfatoxymelatonin were randomized, 20 to each group, to three sublingual sprays twice a day for 20 days of either saline or AEDG (Epitalon Solution-Spray Nanopep, France), while the 35 with age-appropriate normal values formed the control group and are not described as receiving a spray.2,1 FDA notes that the authors reported "distinct positive dynamics of psycho-emotional and general physical condition" in 83% of cases against 25% on placebo, but that no details were provided about how those conditions were assessed.2 FDA lists the limitations as unspecified blinding, short duration and small size, and states that the study did not evaluate sleep outcomes and did not report safety data.2 A sponsor is not named in the PubMed record.10
Epithalamin studies, reported separately
Epithalamin, the pineal extract, has its own human literature, which Jain and colleagues and FDA both keep apart from epitalon.1 Khavinson and Morozov, of the St. Petersburg Institute of Bioregulation and Gerontology, reported in Neuroendocrinology Letters in 2003 on 266 elderly and older people followed for 6 to 8 years, with thymic (Thymalin) and pineal (Epithalamin) bioregulators applied in the first 2 to 3 years, and reported 1.6 to 1.8-fold lower mortality in the Epithalamin-treated group than in controls.12 It is one of three human epithalamin studies in Table 3 of Jain and colleagues, alongside Korkushko and colleagues in 2006 and 2011.1 Jain and colleagues note heterogeneous treatment groups and limited group-specific methodological detail in that report, and state that the interventions included epithalamin and Thymalin, not synthetic epitalon.1
Doses reported in studies
The app lists a typical dose of 5 to 10 mg per day. FDA's briefing document reports that some websites marketing epitalon state doses ranging from 5 mg to 10 mg per day, and lists the proposed products in the withdrawn nominations as 10 mg/mL and 3000 mcg/mL for subcutaneous injection.2
| Setting | Route | Dose reported | Schedule | Source |
|---|---|---|---|---|
| Elderly adults (Korkushko, 2007)1 | Intramuscular1 | 0.01 mg per day1 | 10 days1 | Jain review1 |
| Women, night-shift workers (Ivko, 2020 and 2021)1 | Sublingual1 | 0.5 mg per day1 | 20 days1 | Jain review; FDA briefing2 |
| Retinitis pigmentosa (Khavinson, 2002)1 | Parabulbar injection1 | 5.0 µg per eye1 | Once daily, 10 days1 | Jain review1 |
Sources in this part
Side effects reported
Sources in this part
FDA's briefing document reports that a search of the FDA Adverse Event Reporting System through 8 December 2025 retrieved no reports for epitalon, and that a search of the Human Foods Complaint System through 5 December 2025 retrieved no cases.2 FDA states that it cannot make definitive conclusions about safety from these data alone, that reporting is voluntary, and that compounders under section 503A generally do not report adverse events to FDA.2 The same document states that neither the nominations nor its own search of the published literature identified clinical studies assessing the safety of epitalon in humans.2
In the retinitis pigmentosa study, Jain and colleagues state that no worsening of clinical condition was reported and that no treatment-related complications or adverse effects were described.1 In the 2007 elderly study, the English-language summary states that the preparations had "no side effects," while Jain and colleagues state that the methods for adverse-event ascertainment were limited.9,1 In the sublingual night-shift study, adverse-event data were not reported systematically.1
FDA identifies immunogenicity and aggregation as concerns for peptides given by injection, stating that "there are insufficient data to conclude that epitalon-related BDSs do not present these risks".2 FDA also states that, from the mechanistic standpoint, epitalon "has the potential to be carcinogenic" because it has been shown to activate telomerase and lengthen telomeres, and that longer telomeres are generally associated with increased risk for cancer.2
Bloodwork and markers
Sources in this part
A review by Khavinson and Linkova, quoted in FDA's briefing document, states that the melatonin effect of epithalamin or epithalon depends on the initial degree of preservation of pineal function, with no significant effect in elderly subjects with unchanged pineal function or in young subjects.2 Jain and colleagues state that changes in urinary melatonin metabolites or circadian-gene expression demonstrate physiological effects but do not by themselves establish improvement in clinically meaningful outcomes.1
Regulatory and anti-doping status
FDA
FDA's briefing document states that there is no United States Pharmacopeia or National Formulary monograph for epitalon free base or its acetate form and that neither is a component of an FDA-approved drug.2
FDA evaluated epitalon free base and epitalon acetate for use in insomnia on its own initiative, after two nominations for the 503A bulk drug substances list had been withdrawn.2 Its conclusion was that "a balancing of the criteria weighs against epitalon (free base) or epitalon acetate being placed on that list".2 The stated reasons include that the substances are not well characterized physically and chemically, that there is a lack of evidence to support effectiveness for insomnia, and that there are no clinical data to support safety.2
At its 23 to 24 July 2026 meeting, the Pharmacy Compounding Advisory Committee recommended epitalon for inclusion, contrary to the FDA staff recommendation, by what Jain and colleagues call a "narrow favorable vote".1 The FDA Law Blog reports the count as 7 in favor, 4 against and 1 abstention.13 The app's note records the vote as 7-5-1. The FDA Law Blog reports that opponents pressed on carcinogenicity, citing a proposed mechanism theoretically linked to cancer via telomere signaling.13 Jain and colleagues state that the committee recommendation is advisory and nonbinding and does not constitute FDA approval, establish safety or efficacy, or itself place epitalon on the 503A list.1 Healio reported on 29 October 2026 that HHS issued an interim enforcement policy, citing the July meeting, under which it will not take action against physicians, state-licensed pharmacies or federal facilities compounding a drug using six listed bulk substances, including epitalon, while FDA reviews them.14 Healio adds that, according to the Associated Press, FDA's "scientific staffers had little input on the decision and opposed the changes", and quotes a physician saying that the agency "never added these to the approved list" and that HHS has said the policy is not an FDA endorsement.14
Anti-doping
The WADA 2026 Prohibited List does not name epithalon or epitalon: a search of its full text for epitalon, epithalon and AEDG returned no match.15 Its section S0 is titled "Non-approved substances" and is prohibited at all times, in and out of competition.15 S0 covers "any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use".15 The list text does not state whether epithalon falls under S0.15
Storage and handling
Sources in this part
FDA's briefing document reports that lyophilized epitalon free base is stable at room temperature for 3 weeks, a figure its footnote attributes to a supplier's page.2 It states that the free base is "recommended to be stored desiccated below -18°C" because exposure to moisture greatly decreases the long-term stability of lyophilized peptides, and that a reconstituted solution is stable for 2 to 7 days at 4°C, with storage below -18°C for later use.2 For the acetate, the nominator's certificate of analysis gives long-term storage "in a sealed container at 2°C to 8°C in a fridge or freezer".2 FDA separately reports, citing a second supplier's product page, stability up to three years at -20°C and one year in solvent at -80°C.2
What is not known
Neither FDA's briefing document nor the Jain review reports a half-life, time to peak, bioavailability or dose-ranging study for epitalon in people, and FDA identified no additional nonclinical pharmacokinetic or toxicokinetic studies beyond the rabbit report.2 FDA identified no repeat-dose toxicity, acute toxicity, developmental and reproductive toxicity or 2-year carcinogenicity studies of epitalon free base or epitalon acetate.2 Jain and colleagues state that no adequately powered randomized trial has demonstrated clinical efficacy for aging, longevity, sleep disorders, musculoskeletal disease, pain or another regenerative indication.1 The one registered study returned by a search of ClinicalTrials.gov for epitalon or epithalon, NCT07888595, is a single-group interventional study of several agents in which epitalon is one of five peptides in a topical serum applied at about 1 to 3 mg/mL, so its results would not be results for epitalon alone.3 Jain and colleagues state that an analysis of epitalon in two products sold outside authorized channels confirmed AEDG identity but did not evaluate purity, dosing accuracy, sterility, stability or product safety.1
Frequently asked questions
What is the half-life of epithalon?
FDA's July 2026 briefing document states that no pharmacokinetic data were found for epitalon free base or epitalon acetate, and neither it nor the Jain review reports a half-life.2 The app lists a half-life of about 3 hours and a time to peak of about 30 minutes.
What is epithalon?
Epithalon, also spelled epitalon, is the tetrapeptide Ala-Glu-Asp-Gly (AEDG).1
Is epithalon the same as epithalamin?
No, FDA states that it considers epitalon and epithalamin to be different substances.2
Does epithalon lengthen telomeres?
The telomere lengthening reported in the cited studies is from cultured human cells.4,5 In the 2025 Brunel study, telomere length rose in two normal cell lines after 3 weeks of treatment and in two breast cancer cell lines after 4 days, with telomerase activity rising in the normal cells and ALT activity in the cancer cells, while 4 days of treatment in IBR.3 cells gave no increase.5 A later correction replaced the first three figures of that publication, and Jain and colleagues write that the reported telomerase-activity findings need cautious interpretation.1
Has epithalon been studied in people?
Yes, in a small number of studies: Jain and colleagues count 4 of 28 epitalon publications as involving human participants.1
Is epithalon approved by the FDA?
No, FDA states that epitalon free base and epitalon acetate are not components of an FDA-approved drug.2 In July 2026 the Pharmacy Compounding Advisory Committee recommended epitalon for the 503A bulk drug substances list for insomnia, which the FDA Law Blog reports as a vote of 7 to 4 with 1 abstention and Jain and colleagues describe as a narrow favorable vote that is advisory and nonbinding.13,1 The app's note records that vote as 7-5-1.
Is epithalon banned by WADA?
The 2026 WADA Prohibited List does not name epithalon or epitalon in its text.15 Section S0 prohibits at all times any pharmacological substance not addressed elsewhere in the list and with no current approval by any governmental regulatory health authority for human therapeutic use, and the list does not state whether epithalon falls under it.15
What are the side effects of epithalon?
FDA's briefing document reports no epitalon reports in the FDA Adverse Event Reporting System through 8 December 2025, and states that it cannot draw definitive conclusions about safety from that data alone.2 FDA also states that it found no clinical safety studies and that nonclinical studies were too limited in scope and duration to inform safety.2
Does epithalon affect melatonin?
Small human studies report higher urinary 6-sulfatoxymelatonin or night melatonin in people with reduced pineal function.10,9 A review quoted by FDA reports no significant effect in elderly subjects with unchanged pineal function or in young subjects.2 An in vitro study of rat pineal glands reported no significant effect on melatonin secretion.6
Guides, tools and comparisons
References
- Jain A, et al. Epitalon and Epithalamin: A Narrative Review of Mechanistic, Preclinical, and Clinical Evidence. Int J Mol Sci 2026. PMID 42884164
- US Food and Drug Administration. FDA evaluation of epitalon-related bulk drug substances (epitalon free base and epitalon acetate) for the 503A bulk drug substances list. Briefing document, Pharmacy Compounding Advisory Committee, 23-24 July 2026. FDA briefing document
- ClinicalTrials.gov NCT07888595. Systemic and Topical Geroprotective Rejuvenation Assessed by START/REST Aging Clocks. Frontiers in Bioscience Research Institute and Aging, 2026. NCT07888595
- Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med 2003. PMID 12937682
- Al-Dulaimi S, Thomas R, Matta S, Roberts T. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology 2025. PMID 40908429
- Djeridane Y, Khavinson VKh, Anisimov VN, Touitou Y. Effect of a synthetic pineal tetrapeptide (Ala-Glu-Asp-Gly) on melatonin secretion by the pineal gland of young and old rats. J Endocrinol Invest 2003. PMID 12809170
- Anisimov VN, Khavinson VKh, Popovich IG, et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology 2003. PMID 14501183
- Khavinson V, Razumovsky M, Trofimova S, et al. Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. Neuro Endocrinol Lett 2002. PMID 12195242
- Korkushko OV, Lapin BA, Goncharova ND, et al. Normalizing effect of the pineal gland peptides on the daily melatonin rhythm in old monkeys and elderly people. Adv Gerontol 2007. PMID 17969590
- Ivko OM, Linkova NS, Ilina AR, et al. AEDG peptide regulates human circadian rhythms genes expression during pineal gland accelerated aging. Adv Gerontol 2020. PMID 33280326
- Araj SK, Brzezik J, Mądra-Gackowska K, Szeleszczuk Ł. Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties. Int J Mol Sci 2025. PMID 40141333
- Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett 2003. PMID 14523363
- Snow CD, Palmer KL, Bass M. The PEPTIDE-L Wave Rolls On! PCAC Adds Two More Bulk Drug Substances for the 503A List. FDA Law Blog, 28 July 2026. FDA Law Blog
- HHS further loosens restrictions for several peptides. Healio, 29 October 2026. Healio
- World Anti-Doping Agency. World Anti-Doping Code International Standard, Prohibited List 2026 (copy hosted on segas.gr). WADA 2026 list